September 2022 FDA Recall Pyridostigmine Bromide by Vistapharm, Inc.
D-0018-2023 - cGMP Deviations
This Class II drug recall was voluntarily initiated by Vistapharm, Inc. on September 30, 2022 for the product Pyridostigmine Bromide. The FDA reported the reason for recall as cgmp deviations. The product was distributed Nationwide and the recall is currently terminated.
Recall Number: D-0018-2023
cGMP Deviations: Out of specification for assay of one of the preservative ingredients.
09-30-2022
11-02-2022
1980 cups
Recall Profile & Regulatory Data
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
The firm responsible for the recall.
VistaPharm, Inc.
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
General area of initial distribution.
USA Nationwide
04-30-2024
Product Description About Product Description
Full technical description of the product.
Full technical description of the product.
Pyridostigmine Bromide Oral Solution, USP 60 mg/5 mL Delivers 5 mL, packaged in 5mL unit-dose cup, Rx only, Dist. by: VistaPharm, NDC 66689-406-01
Batch or Lot Expiration Information
Lot# : 832400, Exp 08/2023